Spots Global Cancer Trial Database for Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors
Official Title: A Clinical Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors
Study ID: NCT05098171
Interventions
Study Description
Brief Summary: This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Shanghai Tenth People's Hospital, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
